Clinical trial · Observational
A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
Overall Survival for Metastatic Colorectal Cancer Patients Matched to CHECKMATE-142
NCT05420909CI-TRIAL-00060437completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer (mCRC) | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort 1
- description
- Participants diagnosed with metastatic colorectal cancer (mCRC) selected from the Flatiron Electronic Health Record database
Primary outcomes (2)
- measure
- Overall Survival (OS)
- timeFrame
- Up to 6 years
- measure
- Duration of Systemic Treatment
- timeFrame
- Up to 6 years
- description
- Durations were reported for the first line of therapy prior to the second line (2L) therapy of interest, the 2L therapy of interest, the third line of therapy, and the at least fourth line of therapy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic Colorectal Cancer (CRC) participants in the Flatiron database as defined by: * Diagnosed with CRC (ICD-9 153.x or 154.x or ICD-10 C18x, or C19x, or C20x, or C21x) * Pathology consistent with CRC * At least two documented clinical visits on or after January 1, 2013 * Evidence of Stage IV or recurrent metastatic CRC diagnosed on or after January 1, 2013 * Participants with high levels of microsatellite instability (MSI-H) and/or mismatch repair (MMR) protein deficiency (dMMR) * Participants who received 2L therapy of interest on or after the initial mCRC diagnosis date * Participants who had at least 1 month medical data during the prior to and post periods; however, participants who died within 1 month after the index date will not be excluded from the study Exclusion Criteria: * Participants \<18 years of age at index date * Participants who received clinical trial drug during the prior or post periods
References
Publications (0)
Data not yet available
No reference posted for this study.